STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Corp. - INCY STOCK NEWS

Welcome to our dedicated news page for Incyte (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incyte's position in the market.

News
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL) and Incyte (NASDAQ: INCY) announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. This collaboration aims to explore the use of RP1 in the neoadjuvant setting for cutaneous squamous cell carcinoma (CSCC) and other cancer types. The unique potential of the RPx platform to induce a patient-specific anti-tumor immune response with an off-the-shelf treatment is highlighted, along with the potential to improve patient experience through the combination with Incyte’s oral PD-L1 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
clinical trial
-
News
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Rhea-AI Summary
Syndax Pharmaceuticals and Incyte announce positive topline data from the AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (GVHD). The trial met its primary endpoint with an overall response rate of 74% at a dose of 0.3 mg/kg administered every two weeks. The data also showed a durable response to treatment, with 60% of patients still responding at one year. Syndax and Incyte intend to file a Biologics License Application (BLA) by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
clinical trial
-
News
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Rhea-AI Summary
Incyte (Nasdaq:INCY) announced positive results from its Phase 3 TRuE-AD3 study evaluating ruxolitinib cream in children with atopic dermatitis. The study met its primary endpoint, with more patients achieving treatment success with ruxolitinib cream compared to the control group. The safety profile was consistent with previous data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
clinical trial
News
Incyte to Report Second Quarter Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences earnings
-
News
MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
Rhea-AI Summary
Opzelura® (ruxolitinib) cream has been granted marketing authorization by the MHRA for the treatment of non-segmental vitiligo with facial involvement in the UK. The approval is based on Phase 3 data showing improved repigmentation with longer treatment duration. Vitiligo affects around 1 in 100 people in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
-
News
LYMPHOMA THERAPY NOW APPROVED FOR AUSTRALIAN PATIENTS With Diffuse Large B-cell Lymphoma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
News
bit.bio Strengthens Leadership Team With Appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relations
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
management
-
News
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none
-
News
Incyte to Present at Upcoming Investor Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
conferences
News
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
Stock INCY logo
Incyte Corp.

Nasdaq:INCY

INCY Rankings

#710 Ranked by Market Cap
#3820 Ranked by Stock Gains
N/A Ranked by Dividends

INCY Stock Data

12.09B
186.98M
1.58%
100.2%
3.59%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
US
Wilmington

About INCY

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.